美国退伍军人痛风队列:别嘌醇依从性及其预测因素
该全国性队列研究利用美国退伍军人事务部2002至2016年数据库,纳入264 614例新使用别嘌醇的痛风患者,评估与高依从性(药物持有率>80%)相关的因素。多因素分析显示,高龄、较高体重指数、合并症评分≥1、兵役关联≥50%、社区门诊就诊及农村居住与较高依从性相关;黑人或西班牙裔种族、非风湿科医生诊疗、起始剂量>100 mg/日、既往一年内使用别嘌醇、部分美国地区及基线血尿酸≥480 μmol/L与较低依从性相关。
要点
- 高龄、较高BMI、合并症评分≥1、兵役关联≥50%、社区门诊及农村居住与别嘌醇高依从性相关。
- 黑人或西班牙裔、非风湿科医生诊疗、起始剂量>100 mg/日、既往一年内使用别嘌醇与低依从性相关。
- 基线血尿酸<360 μmol/L与较高依从性相关,而480–<600及600–<720 μmol/L与较低依从性相关。
核心结论
- 研究识别了多个与别嘌醇高依从性相关的重要因素,可供临床医生和政策制定者针对患者、提供者或系统层面的可干预因素改善依从性和痛风管理。
研究设计与样本
- 美国退伍军人事务部2002至2016年全国队列研究,采用新使用者设计,纳入264 614例符合标准(痛风ICD-9编码、新使用别嘌醇、至少12个月观察)的患者。
- 采用Andersen卫生服务利用模型和多变量校正logistic回归分析,以药物持有率>80%定义别嘌醇依从性。
关键数值与推荐
- 别嘌醇依从性定义为药物持有率(使用天数除以处方天数)>80%。
- 纳入标准:痛风ICD-9编码274.x在门诊出现≥2次或住院出现≥1次;新使用别嘌醇;至少12个月观察。
临床怎么用
- 临床医生可关注黑人或西班牙裔、非风湿科医生诊疗、起始剂量>100 mg/日、既往一年内使用别嘌醇、基线血尿酸≥480 μmol/L等低依从风险因素,针对性加强随访和患者教育。
- 政策制定者可考虑针对社区门诊、农村居住等系统层面因素优化资源配置,以改善别嘌醇依从性和痛风整体管理。
局限性
- 研究基于美国退伍军人事务部数据库,结果外推至其他人群需谨慎。
- 依从性通过药物持有率评估,可能无法完全反映实际服药行为。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Allopurinol is a frequently used, effective, and affordable medication for gout. However, poor adherence to allopurinol is a key reason for patients not reaching treatment goals. The aim of this study was to comprehensively assess factors associated with high allopurinol adherence in gout. METHODS: In this national cohort study, we used the health-care databases of the US Department of Veterans Affairs (VA) from 2002 to 2016 and a new-user design to assess potential predicting factors of allopurinol adherence. Veterans were included in this study if they had International Classification of Diseases (ninth revision) code 274.x for gout in two or more outpatient encounters or one or more inpatient encounters during 2002-16; incident allopurinol use; and at least 12 months of observation. Potential predictors of allopurinol adherence (defined as medication possession ratio [days used divided by days prescribed] of >80%) were examined using Andersen's health-care utilisation model and multivariable-adjusted logistic regression analyses. FINDINGS: Between Oct 1, 2002, and Sept 30, 2016, 565 812 potentially eligible patients were included in the VA database, of whom 264 614 (46·8%) met the eligibility criteria and were included in the study cohort. The mean age was 67·8 years (SD 11·7) and mean body-mass index was 33·0 kg/m2 (6·4). Factors significantly associated with higher odds of allopurinol adherence in multivariable-adjusted analyses were older age (odds ratio 1·01, 95% CI 1·01-1·01); Deyo-Charlson comorbidity index score of 1 (1·05, 1·02-1·07) or 2 or more (1·05, 1·03-1·07) versus a score of 0; higher body-mass index (all categories from 25 to <30 [1·12, 1·08-1·17] to ≥45 [1·47, 1·39-1·55] vs 18·5 to <25); a military service connection of 50% or higher (1·37, 1·29-1·46) versus 0%; care in a community-based outpatient clinic (1·11, 1·08-1·14) versus in a VA Medical Center; and rural residence (1·02, 1·00-1·05). Factors significantly associated with lower odds of allopurinol adherence were black (0·74, 0·72-0·76), Hispanic (0·68, 0·65-0·72), or other race or ethnicity (0·86, 0·82-0·89) versus white race; non-rheumatologist care provider (0·83, 0·79-0·88); allopurinol start dose of 101-200 mg per day (0·93, 0·91-0·95) or more than 300 mg per day (0·75, 0·72-0·79) versus 100 mg per day or less; or allopurinol use in the previous year (0·80, 0·79-0·82). Compared with residence in the Midwest, patients in other US regions had lower odds of adherence (mid-Atlantic 0·89, 0·87-0·92; northeast 0·84, 0·81-0·87; south 0·85, 0·83-0·88; west 0·86, 0·83-0·89). Compared with a baseline serum urate of 360 to less than 480 μmol/L, serum urate of less than 360 μmol/L was associated with higher odds of adherence (1·28, 1·25-1·32), whereas baseline serum urate of 480 to less than 600 μmol/L (0·86, 0·84-0·88) or 600 to less than 720 μmol/L (0·92, 0·89-0·94) was associated with lower odds of adherence. INTERPRETATION: We identified several important factors associated with high allopurinol adherence. Clinicians and policy makers can now target modifiable factors at the patient, provider, or systems level, with the aim of improving allopurinol adherence, and thereby overall gout care.
引用
- Singh JA, Richman J, Yang S, et al. Allopurinol adherence and its predictors in gout: a national cohort study in US veterans. Lancet Rheumatol. 2020. PMID: 33215163. doi:10.1016/S2665-9913(20)30029-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。